Fig. 1

SuperMApo treatment attenuates ongoing MOG-induced EAE in C57BL/6 mice. a Clinical score of EAE mice treated twice (black arrows) with SuperMApo (n = 6 mice) or with vehicle (n = 5 mice). Data from a representative experiment out of 3 showing similar results. b Representative H&E and Luxol Fast Blue stainings of spinal cords 72 h after the first injection of SuperMApo or vehicle. Spinal cord inflammation in mice is evaluated by inflammatory index and scored in H&E sections. Demyelination is scored in Luxol Fast Blue sections. Demyelinated areas are identified with black arrows. Scale bar, 80 µM. Data pooled from 3 independent experiments (n = 15 mice per condition). c Total number of CD45⁺ leukocytes in spinal cords 72 h after the first SuperMApo (n = 5 mice) or vehicle (n = 5 mice) treatment. Data from a representative experiment out of 3 showing similar results. d Total number of Th1 (IFN-γ⁺CD4⁺CD3⁺), Th17 (IL-17⁺ CD4⁺CD3⁺), Treg (Foxp3⁺CD25⁺CD4⁺CD3⁺), Tc1 (IFN-γ⁺ CD8⁺CD3⁺), dendritic cells (DC) (CD11c⁺CD11b⁻), plasmacytoid DC (mPDCA⁺CD11c⁺CD11b⁻) and macrophages (CD11b^hiCD45⁺). Data from a representative experiment out of 3 showing similar results. e Percentages of cells depicted in d. f Ex vivo analysis of macrophages co-stimulation and class-II molecule expression issued from SuperMApo or vehicle-treated EAE mice as MFI (f), as well as inflammatory cytokine content (g). Data pooled from 4 independent experiments, 20 mice per condition. Statistical significance was assessed by using ANOVA two-way and Bonferroni posttest (a) or unpaired two-tailed Student’s t test (b–g) (*p < 0.05; **p < 0.01; ***p < 0.001)